JP3782591B2 - 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用 - Google Patents

置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用 Download PDF

Info

Publication number
JP3782591B2
JP3782591B2 JP29701198A JP29701198A JP3782591B2 JP 3782591 B2 JP3782591 B2 JP 3782591B2 JP 29701198 A JP29701198 A JP 29701198A JP 29701198 A JP29701198 A JP 29701198A JP 3782591 B2 JP3782591 B2 JP 3782591B2
Authority
JP
Japan
Prior art keywords
hydrogen
chlorine
formula
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP29701198A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11302257A5 (enExample
JPH11302257A (ja
Inventor
クラウス・ヴアイトマン
カール−ハインツ・バリングハウス
ゲオルク・チヤンク
ウルリヒ・ヴエルナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of JPH11302257A publication Critical patent/JPH11302257A/ja
Publication of JPH11302257A5 publication Critical patent/JPH11302257A5/ja
Application granted granted Critical
Publication of JP3782591B2 publication Critical patent/JP3782591B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP29701198A 1997-10-20 1998-10-19 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用 Expired - Lifetime JP3782591B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287:1 1997-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005254578A Division JP4691419B2 (ja) 1997-10-20 2005-09-02 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用

Publications (3)

Publication Number Publication Date
JPH11302257A JPH11302257A (ja) 1999-11-02
JPH11302257A5 JPH11302257A5 (enExample) 2005-10-27
JP3782591B2 true JP3782591B2 (ja) 2006-06-07

Family

ID=7846053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP29701198A Expired - Lifetime JP3782591B2 (ja) 1997-10-20 1998-10-19 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用
JP2005254578A Expired - Lifetime JP4691419B2 (ja) 1997-10-20 2005-09-02 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005254578A Expired - Lifetime JP4691419B2 (ja) 1997-10-20 2005-09-02 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用

Country Status (24)

Country Link
US (1) US6093730A (enExample)
EP (2) EP1538160B1 (enExample)
JP (2) JP3782591B2 (enExample)
KR (1) KR100618922B1 (enExample)
CN (1) CN1117079C (enExample)
AR (1) AR013696A1 (enExample)
AT (2) ATE432940T1 (enExample)
AU (1) AU755714B2 (enExample)
BR (1) BR9804504B1 (enExample)
CA (2) CA2250664A1 (enExample)
CZ (1) CZ337298A3 (enExample)
DE (3) DE19746287A1 (enExample)
DK (2) DK0911340T3 (enExample)
ES (2) ES2328156T3 (enExample)
HU (1) HUP9802422A3 (enExample)
ID (1) ID21115A (enExample)
IL (1) IL126638A0 (enExample)
NO (1) NO312365B1 (enExample)
NZ (1) NZ332363A (enExample)
PL (1) PL192354B1 (enExample)
PT (1) PT911340E (enExample)
SG (1) SG87776A1 (enExample)
TR (1) TR199802106A3 (enExample)
ZA (1) ZA989505B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275014A1 (en) * 2000-05-30 2001-12-11 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
ES2414706T3 (es) * 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1893186A2 (en) * 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
DE602006014843D1 (de) 2005-06-15 2010-07-22 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
DK2044028T3 (da) 2006-01-27 2012-08-20 Fibrogen Inc Cyanoisoquinolinforbindelser til stabilisering af den hypoxiinducerende faktor (HIF)
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
BRPI0710048A2 (pt) * 2006-03-30 2011-08-02 Lg Electronics Inc método e aparelho para decodificar / codificar um sinal de vìdeo
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
BRPI0713350B1 (pt) 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US7635715B2 (en) 2006-12-18 2009-12-22 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2683956C (en) 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008130508A1 (en) 2007-04-18 2008-10-30 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
TWI485150B (zh) * 2009-07-17 2015-05-21 Japan Tobacco Inc 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2013013609A1 (en) * 2011-07-22 2013-01-31 Zhejiang Beta Pharma Incorporation Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
EP2776023B1 (en) 2011-10-25 2016-03-09 Janssen Pharmaceutica, N.V. Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
CN109369524A (zh) 2012-07-16 2019-02-22 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
HUE034409T2 (en) * 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
WO2014070859A1 (en) * 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CN105377242A (zh) 2013-06-06 2016-03-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
TWI846166B (zh) 2013-11-15 2024-06-21 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
JP2018502882A (ja) 2015-01-23 2018-02-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
EP4667059A2 (en) * 2015-05-28 2025-12-24 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
JP6884714B2 (ja) * 2015-07-09 2021-06-09 インスメッド インコーポレイテッド 肺疾患及び肺損傷を治療するための組成物及び方法
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2019139956A2 (en) * 2018-01-09 2019-07-18 Cornell University Prevention and treatment of organ fibrosis
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
US20210299116A1 (en) * 2018-08-03 2021-09-30 Cornell University Methods for reducing abnormal scar formation
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
EP0548883A1 (de) * 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DK0650961T3 (da) * 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
ID21115A (id) 1999-04-22
HUP9802422A3 (en) 2002-02-28
PL329274A1 (en) 1999-04-26
DK1538160T3 (da) 2009-10-05
TR199802106A2 (xx) 1999-05-21
CN1117079C (zh) 2003-08-06
KR100618922B1 (ko) 2007-04-25
CA2251647A1 (en) 1999-04-20
CZ337298A3 (cs) 1999-05-12
ATE432940T1 (de) 2009-06-15
NO984877L (no) 1999-04-21
ATE299148T1 (de) 2005-07-15
NO312365B1 (no) 2002-04-29
TR199802106A3 (tr) 1999-05-21
JPH11302257A (ja) 1999-11-02
HU9802422D0 (en) 1998-12-28
EP1538160A1 (de) 2005-06-08
DE19746287A1 (de) 1999-04-22
CA2251647C (en) 2011-08-30
ES2328156T3 (es) 2009-11-10
ES2245471T3 (es) 2006-01-01
EP0911340A2 (de) 1999-04-28
SG87776A1 (en) 2002-04-16
JP2006056894A (ja) 2006-03-02
HK1019605A1 (en) 2000-02-18
EP0911340B1 (de) 2005-07-06
IL126638A0 (en) 1999-08-17
EP1538160B1 (de) 2009-06-03
DK0911340T3 (da) 2005-11-07
BR9804504A (pt) 2001-05-22
NZ332363A (en) 2000-04-28
CN1218802A (zh) 1999-06-09
PT911340E (pt) 2005-09-30
DE59814365D1 (de) 2009-07-16
PL192354B1 (pl) 2006-10-31
CA2250664A1 (en) 1999-04-20
NO984877D0 (no) 1998-10-19
DE59812907D1 (de) 2005-08-11
EP0911340A3 (de) 1999-07-07
AU755714B2 (en) 2002-12-19
JP4691419B2 (ja) 2011-06-01
ZA989505B (en) 1999-04-20
AU8941398A (en) 1999-05-06
AR013696A1 (es) 2001-01-10
BR9804504B1 (pt) 2009-01-13
HUP9802422A2 (hu) 1999-08-30
US6093730A (en) 2000-07-25
KR19990037182A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
JP3782591B2 (ja) 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用
EP0012845B1 (en) Tetrahydroisoquinoline compounds, process for preparing same and pharmaceutical compositions containing them
TW541316B (en) Prodrugs of thrombin inhibitors
AU743750B2 (en) 3-hydroxypyridine-2-carboxamidoesters, their preparation and their use as pharmaceuticals
KR20000065090A (ko) 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
CZ289356B6 (cs) Substituované amidy heterocyklických karboxylových kyselin, způsob jejich přípravy a jejich pouľití jako léčiva
JP2002542164A (ja) 補体プロテアーゼの低分子インヒビター
AU3646993A (en) New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
WO1992018488A1 (en) Novel oxazinone derivative
JPH05507295A (ja) Ｎ―（α―置換―ピリジニル）カルボニルジペプチド抗高血圧剤
RO104347B1 (en) Production method of amids acids cyclomethylen - 1,2 - dicarboxylic
US5166154A (en) Imidazo[1,2-a]piperazines
RU2168493C2 (ru) Производные l-аргинина, способ их получения, фармацевтическая композиция, обладающая ингибирующей no-синтазу активностью
SK322003A3 (en) Thrombin inhibitors comprising an aminoisoquinoline group
RU2117660C1 (ru) Сложные эфиры ацилсульфонамидо- и сульфонамидопиридин-2-карбоновой кислоты, содержащая их фармацевтическая композиция и способ ее получения
MXPA98008644A (en) Amques of substitute isoquinolin-3-carboxylic acid, its preparation and its employment as a medicine
KR960008242B1 (ko) 벤조옥사디논유도체
JPS633000A (ja) ペプチド誘導体類及びそれらの製造方法
JP2002522060A (ja) エキソケリンを合成するための新規方法
JP2654848B2 (ja) 新規イソキノリン誘導体またはその酸付加塩
JPH04338330A (ja) チロシン硫酸塩からなる血小板凝集阻止剤
JPH07304744A (ja) 新規イソキノリン誘導体及びその酸付加塩
EP0186431A1 (en) Anti-hypertensive octahydro-6-azaindole dipeptide derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050902

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050902

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20051005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060310

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100317

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110317

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120317

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130317

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term